Just announced this morning, the phase III clinical trial conducted by Moderna has shown >94% efficacy and the company plans to apply for emergency use of the vaccination in the coming weeks.
Also in the news was a statement from U.S. Health and Human Services (HHS) Secretary Alex Azar indicating that although these two vaccines are two-dose vaccines, there should enough to vaccinate 20 million Americans by December. Additionally, Secretary Azar mentioned that by quarter two of 2021 there should be enough supply to vaccinate ALL Americans who wish to get vaccinated.
As you may have guessed, this new information has set the DOW futures soaring near 30,000. Moderna stock is also up significantly, as shown in the snip it below where the 1-year graph indicates that the stock was trading just over $18/share in April and is now expected to open over $100/share.